Univercells Technologies agreed to collaborate with Repligen to integrate real-time monitoring capabilities and enhance the development and manufacturing of viral vectors and vaccines. Repligen’s MAVEN® Real Time Glucose Control Platform, recently acquired from 908 Devices, will be used to perform real-time monitoring of glucose and lactate in the range of scale-X
bioreactors for adherent cell culture processes.
![The MAVEN is designed to monitor and control glucose and lactate concentrations during cell culture and fermentation without removing any media volume from the bioreactor. [Repligen]](https://www.genengnews.com/wp-content/uploads/2025/07/Maven_product-image-1500x1001-1-1024x684.jpg)
“This collaboration brings real-time process analytical technology (PAT) to our scale-X bioreactors, eliminating manual nutrient testing and significantly increasing data resolution,” said Marie Jourdan, director of product management at Univercells Technologies. “With more frequent and automatic measurements, we can feed data into our SkaiaTM vision application software model for an even more accurate estimation of cell growth.”
The MAVEN is designed to monitor and control glucose and lactate concentrations during cell culture and fermentation without removing any media volume from the bioreactor, according to Wolfgang Kuennecke, vp, bioanalytic, enzymatic analyzers from Repligen. Real-time insights into cellular metabolism make it easier to optimize media and develop feeding and control strategies, he continued, adding that users can detect and react to process changes with monitoring of glucose and lactate as often as every two minutes and up to 720 glucose-lactate data points per day.
“Compatibility of technologies is critical to commercializing advanced therapies,” pointed out Kuennecke. “In this alignment, we have combined MAVEN and the scale-X bioreactors via a custom diffusion manifold so that developers can expand their toolbox simply. This integration helps developers to concentrate on the needs of their cells and create the optimum process conditions for their growth.”
The post Repligen and Univercells Partner to Enable Real-Time Viral Vector and Vaccine Biomanufacturing Monitoring appeared first on GEN – Genetic Engineering and Biotechnology News.
